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syndromes, but may be less effective in identifying novel ge-
netic causes of short stature in individual families. Utilized in 
the clinic, whole exome sequencing can provide clinically 
relevant diagnoses for these patients. Rare syndromic causes 
of short stature may be underrecognized and underdiag-
nosed in pediatric endocrinology clinics. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Short stature is one of the most common reasons for 
presentation to pediatric endocrinology clinics in the 
United States. Although there are many known causes of 
short stature, in most cases of non-familial short stature, 
there is no identifiable cause and the patient is classified 
as having idiopathic short stature (ISS)  [1–3] . Without a 
definitive diagnosis, it can be difficult for clinicians to 
provide optimal treatment recommendations and to 
counsel patients on disease progression and recurrence 
risk  [1] .
 It is well known that some cases of short stature have 
a single predominant genetic cause. These include Tur ner 
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 Abstract 
 Background/Aims: Short stature is a common reason for 
presentation to pediatric endocrinology clinics. However, 
for most patients, no cause for the short stature can be iden-
tified. As genetics plays a strong role in height, we sought to 
identify known and novel genetic causes of short stature. 
 Methods: We recruited 14 children with severe short stature 
of unknown etiology. We conducted whole exome sequenc-
ing of the patients and their family members. We used an 
analysis pipeline to identify rare non-synonymous genetic 
variants that cause the short stature.  Results: We identified 
a genetic cause of short stature in 5 of the 14 patients. This 
included cases of floating-harbor syndrome, Kenny-Caffey 
syndrome, the progeroid form of Ehlers-Danlos syndrome, 
as well as 2 cases of the 3-M syndrome. For the remaining 
patients, we have generated lists of candidate variants.  Con-
clusions: Whole exome sequencing can help identify genet-
ic causes of short stature in the context of defined genetic 
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syndrome, mutations in the  SHOX  gene ,  and mutations 
in numerous genes in the growth hormone/insulin-like 
growth factor axis  [1, 4] . Additionally, there are currently 
more than 250 mendelian syndromes or skeletal dyspla-
sias associated with short stature that have had a causal 
gene identified, and this list is rapidly expanding. Studies 
have also revealed an increased burden of copy number 
variants (CNVs), particularly of rare deletions, in patients 
with short stature  [5–7] . Thus, rare genetic sequence and 
CNVs likely explain some cases of ISS, and it is important 
to identify these causes.
 We hypothesized that rare highly penetrant non-syn-
onymous genetic variants could explain some cases of 
short stature of unknown cause. Strictly speaking, ISS re-
fers to a condition characterized by normal birth weight, 
normal body proportions, no evidence of endocrine ab-
normalities, and no nutritional or psychosocial problems 
 [2] . In this study, we sought to identify known or novel 
genetic causes of short stature in a cohort of patients with 
severe short stature presenting to an endocrine clinic, a 
third of whom met criteria for ISS. As part of a larger ge-
netic study of patients with short stature  [8] , we selected 
a cohort of 14 patients with severe short stature and con-
ducted whole exome sequencing and genome-wide copy 
number assessment in the patients and their family mem-
bers to identify genetic etiologies for their short stature. 
We successfully identified the genetic cause of short stat-
ure in 5 patients. Our report highlights the ability for 
whole exome sequencing to identify clinically important 
rare genetic disorders.
 Methods 
 Patient Recruitment 
 This study was approved by the Institutional Review Board of 
Boston Children’s Hospital. All participants or their legal guard-
ians provided written informed consent. Subjects were recruited 
as part of a larger cohort searching for novel genetic etiologies of 
short stature in individuals with no known genetic etiology. Inclu-
sion criteria for the larger cohort have previously been described 
 [8] . Over the course of our study, we have selected individuals for 
exome sequencing who were predicted to have a higher likelihood 
of a monogenic cause of their short stature. Herein, we report the 
results of our exome sequencing studies of these patients. Specifi-
cally, we selected patients with severe short stature (>3 SD below 
mean for age and gender at study enrollment) who had received a 
prior standard clinical workup that was unable to identify a ge-
netic cause of their short stature. However, subjects were allowed 
to have additional medical comorbidities, dysmorphic features, or 
other hormonal deficiencies as long as these alternate medical 
problems did not provide a clear explanation for the subject’s short 
stature. We selected patients only if DNA samples were available 
from both parents, and we gave preference to individuals for 
whom a DNA sample was available for a sibling as well. The total 
number of individuals selected for sequencing was based on the 
available budget for the project. In separate analyses, we have ex-
amined patients with more severe clinically diagnosed syndromes 
and were able to provide genetic diagnoses in a subset of these pa-
tients  [9, 10] .
 Sequencing 
 Whole exome sequencing of the participants was conducted 
from genomic DNA isolated from blood or saliva and was per-
formed at the Broad Institute (Cambridge, Mass., USA) as previ-
ously described  [11] . We included in our study only variants that 
passed all quality filters or received a VQSR SNP quality score 
>98.50. All presumptive causal variants were verified by Sanger 
sequencing. As de novo variants are highly susceptible to sequenc-
ing and variant calling artifacts, we took several steps to remove 
potentially false-positive calls. First, we visually inspected all 
aligned sequencing reads for de novo variants using the Integrative 
Genomics Viewer  [12] . Second, we removed any calls based on low 
sequencing coverage (<10 sequencing total reads in the patient and 
in both parents). Finally, we Sanger sequenced and/or genotyped 
remaining de novo variants in the patients as well as their parents. 
Sequencing primers and genotyping probes are available upon re-
quest.
 Chromosomal Microarray 
 DNA samples from patients and unaffected family members 
were analyzed using Agilent SurePrint G3 custom 4×180K com-
parative genomic hybridization (CGH) and SNP microarray (Agi-
lent Technologies) as previously described  [13] . Candidate CNVs 
were filtered using standard clinical practices in the DNA diagnos-
tic laboratory at Boston Children’s Hospital.
 Variant Filtering 
 We hypothesized that these patients had rare highly penetrant 
genetic variants causing their short stature. We therefore only con-
sidered variants that were either not present or had minor allele 
frequency <1% in the 1000 Genomes Project (November 2012 re-
lease)  [14] , the National Institutes of Health Heart, Lung, and 
Blood Institute exome variant server (ESP 6500 release)  [15] , and 
the 50 control exomes whose variants were called in conjunction 
with our subject’s variants. For de novo heterozygous variants and 
for consideration of dominant inheritance, we further restricted 
our analyses to variants not present in any of the above databases 
or in dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/). Anal-
ysis was limited to variants that were predicted to have an effect on 
the protein coding sequence, including non-synonymous codon 
changes, frameshift variants, splice site variants, and coding indels.
 We applied additional filters to consider several potential pat-
terns of inheritance: (1) de novo – a novel variant present in the 
patient but neither parent, (2) homozygous recessive – a single 
candidate variant present in the homozygous state in the patient 
and heterozygous in each parent, (3) compound heterozygous – 
two or more candidate variants in a single gene with at least a sin-
gle candidate variant present in each parent, (4) and X-linked re-
cessive in male patients – a maternally inherited candidate variant 
on the X chromosome. For two families, we additionally consid-
ered a dominant mode of inheritance as described below.
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 Results 
 Description of Cohort 
 We selected 14 patients with severe short stature (>3 
SD below the mean adjusted for age and gender at time of 
recruitment). The patients’ heights and additional clinical 
features are listed in  table 1 (detailed clinical descriptions 
are provided in online suppl. File 1; for all online suppl. 
material, see www.karger.com/doi/10.1159/000360857). 
For 12 families, DNA was available from the patient, both 
parents, and one sibling. For two families (P10 and P14), 
DNA was available from the patient and unaffected par-
ents only. There were 6 male and 8 female patients in the 
cohort. Seven of the patients in the cohort were treated 
with growth hormone therapy, but with variable clinical 
efficacy and for various lengths of time ( table 1 ).
 The heights of the affected individuals ranged from 
–2.82 to –4.33 SD. These heights represent the most cur-
rent height measurement, or if the patient has received 
GH therapy, the measurement immediately prior to GH 
administration (heights at enrollment are listed in online 
suppl. File 1). Immediate family members had heights 
above –2 SD and were considered to be unaffected except 
for families P04 and P05 where other family members had 
heights below –2 SD. All patients had undergone detailed 
evaluations in the pediatric endocrinology clinic and 
some had undergone additional evaluation by a clinical 
geneticist. All patients also had other genetic tests per-
 Table 1.  Patient characteristics: heights for all participants are shown as the height z-scores adjusted for age and gender of the participant
Subject
No.
Gender Patient’s
height
Mother’s
height
Father’s
height
Sibling’s
height
Patient 
birth weight
Additional clinical features GH treatment
P01 M –4.05 –0.44 –1.04 –0.76 5 GH deficiency, osteopenia, delayed bone age, 
febrile seizures
yes, with good 
response
P02 M –4.33 –0.12 1.07 NA 8 hyperflexible joints, hyperextensible skin, 
 bilateral radioulnar synostosis
yes, with no 
response
P03 M –3.54 –1.21 –1.81 –1.87 <1 IUGR, low IGF-1, vitiligo yes, with mild 
transient response
P04 F –3.84 –0.34 –2.65 –2.32 <1 SGA, relatively early puberty treated with 
histrelin implant
yes, with mild 
transient response
P05 F –3.15 –0.50 –3.46 –2.42 <1 SGA, thoracic hemivertebrae not treated
P06 F –2.89 –1.28 –1.45 –1.95 3 borderline SGA, ISS, anxiety disorder not treated
P07 F –2.98 0.42 0.16 –0.26 <1 SGA, dysmorphic facial appearance, scoliosis, 
tethered cord, bilateral polycystic kidneys, 
hypothyroidism, and developmental delay
not treated
P08 F –3.25 –0.89 –0.64 –0.17 8 ISS not treated
P09 M –3.28 –0.17 –1.74 NA <1 SGA yes, but immediately 
discontinued due to 
side effects
P10 F –3.30 1.50 0.45 NA (trio) 8 ISS, delayed bone age not treated
P11 M –4.17 1.54 2.98 –0.41 <1 SGA, hypergonadotropic hypogonadism yes, with moderate 
response
P12 F –3.11 –1.03 –1.58 –0.21 3 borderline SGA, delayed bone age not treated
P13 M –2.82 –0.18 –1.21 –0.35 21 ISS, delayed bone age not treated
P14 F –5.99 0.52 –1.85 NA (trio) 20 dental abnormalities, myopia yes, with moderate 
response
 NA indicates sibling height not available. Patient birth weights are percentiles adjusted for gestational age and gender. More detailed 
clinical descriptions can be found in the online supplementary File 1.
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formed clinically (karyotypes, chromosomal microar-
rays, or diagnostic sequencing of candidate genes). Thus, 
prior to whole exome sequencing, for this cohort of pa-
tients, no cause of the short stature was identified despite 
extensive prior clinical evaluation (details are provided in 
online suppl. File 1).
 Variants Identified by Whole Exome Sequencing 
 Exome sequencing was performed to identify mono-
genic causes of short stature. Following the sequencing 
and filtering as described in Methods, we identified can-
didate variants for each patient ( table 2 ). On average per 
patient, we identified 1.1 (range 0–3) de novo variants, 0.5 
(range 0–4) autosomal homozygous variants, 2.2 (range 
0–4) X-linked hemizygous variants (for male patients), 
and 3.3 (range 0–8) genes with variants fitting a com-
pound heterozygous model. We note that the rate of de 
novo variants we observed is higher than the expected 
number of non-synonymous de novo variants expected 
(approx. 0.65)  [16] . However, the rate of de novo muta-
tions in patients was similar to the rate found in paired 
unaffected siblings (average 0.75 de novo variants per sib-
ling, p value of 0.43, two-tailed paired t test).
 In addition to whole exome sequence analysis, CNVs 
were assessed using a CGH+SNP microarray. After stan-
dard CNV filtering, we detected rare CNVs in 4 patients. 
Patient P02 had a deletion of  TFP1 (transferrin pseudo-
gene 1) that was inherited from the unaffected father. Pa-
tient P04 had a deletion of  JAKMIP1 (encodes Janus ki-
nase and microtubule-interacting protein 1) that was in-
herited from the unaffected mother. Patient P11 had a 
duplication of  ARPC1A  (encoding actin-related protein 
2/3 complex, subunit 1A) of unknown clinical signifi-
cance and parental microarray data was unavailable. Pa-
tient P14 had a 493-kb duplication on chromosome 
14q24.3, but this duplication was also found in the moth-
er. Thus, no likely pathogenic CNVs were identified. No 
runs of homozygosity (>10 Mb) were detected in any pa-
tient to suggest uniparental disomy or parental consan-
guinity.
 For each patient, we then manually searched in the On-
line Mendelian Inheritance of Man (OMIM) database and 
PubMed for known disease associations with the candidate 
variants. In silico predictions of functional effect of mis-
sense variants was assessed with the PolyPhen2 prediction 
tool  [17] . All genetic diagnoses were made in the context 
of the patient’s clinical features. We identified the genetic 
cause of short stature in 5 of the cases, including 2 cases of 
3-M syndrome, 1 case of floating-harbor syndrome, 1 case 
of the Kenny-Caffey syndrome, and 1 case of Ehlers-Dan-
los syndrome progeroid variant. In the remaining 9 cases, 
we generated a list of candidate genes based on our variant 
 Table 2.  Number of variants per patient
Subject No. Compound heterozygous De novo heterozygous Autosomal recessive X-linked recessive
P01 4 (TLDC1, LTBP4, TTN, PELI3) 1 (ZBED4) 1 (KCNT1) 3 (BTK, GPKOW, MAGEE2)
P02 3 (B4GALT7, GPR98, PYGB) 1 (PPFIA1) 0 4 (ACE2, BCORL1, IL13RA2, VSIG1)
P03 1 (PCDH15) 2 (IKZF4, PDXP) 0 1 (PHF16)
P04 3 (RNF123, BAZ2B, SH3TC1) 2 (LRRC6, HSP90AB1) 0 female
P05 3 (SV2C, MMS19, TAS2R9) 0 0 female
P06 3 (ATM, AHNAK2, LRP1B) 0 1 (FAM129A) female
P07 4 (MYCBP2, LRP1B, PMFBP1, C17ORF66) 3 (KLHL26, NUCB1, SRCAP) 0 female
P08 4 (TTN, COL2A1, ANO5, ZNF507) 0 0 female
P09 6 (AFF1, DKFZ, FAM129C, LRRC14B,
MUC5B, NOL6)
0 4 (ABCA13, OBSL1
(2), PKD1L1)
4 (ACOT9, ARHGEF6, P2RY4, WAS)
P10 3 (ATF6B, COL6A6, MAP1A) 2 (FCGR1B, BTK) 0 female
P11 0 1 (FAM134A) 1 (CUL7) 0
P12 8 (ABCA12, CACNA1G, HERC2, MSLNL,
NBEAL2, OGFOD2, PKD1L1, PLCG2)
1 (NEFM) 0 female
P13 3 (CP, RALGAPA1, DTX2) 1 (PIK3AP1) 0 1 (SSX7)
P14 1 (AL359075.1) 2 (FAM111A, LRRC30) 0 female
Average 3.29 1.14 0.50 2.17
 Shown is the number of variants (or number of genes for compound heterozygous) meeting our filtering criteria (as described in Methods) for each pa-
tient. Listed in parentheses are the candidate genes meeting filtering criteria for each patient (details of these candidate variants are provided in online sup-
plementary table 2). The causal genes are highlighted in bold.
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filtering criteria (online suppl. table 2). We did not have 
enough evidence to assign causality for these candidate 
variants, but a few of these variants are interesting candi-
dates (see Discussion). Details of all candidate variants are 
provided in online supplementary table 2.
 Patients with Identified Genetic Cause 
 As a result of our exome sequencing and analysis, we 
were able to identify a genetic cause of the short stature 
for 5 patients ( table 3 ), 2 of whom we have previously de-
scribed (P02 and P11). Patient P02 received a genetic di-
agnosis of the progeroid form of Ehlers-Danlos syndrome 
due to compound heterozygous mutations in  B4GALT7 
 [19] .  The patient presented with various skeletal abnor-
malities (most notably congenital dislocations of the el-
bow), skin hyperextensibility, and joint hyperflexibility, 
in addition to severe short stature. Patient P11 received a 
genetic diagnosis of the 3-M syndrome due to recessive 
mutations in  CUL7  [11] . This patient was born small for 
gestational age (SGA) and had minor dysmorphic facial 
features in addition to severe short stature. Hypergonad-
otropic hypogonadism was discovered in this patient sub-
sequent to the genetic diagnosis.
 We report for the first time 3 other patients who we 
were able to diagnose using whole exome sequencing. Pa-
tient P09 is a South-Asian male born SGA (2.25 kg). Skel-
etal survey revealed proportionate short stature and grac-
ile bones, but no distinct skeletal dysplasia was identified. 
Growth hormone and thyroid hormone axes were nor-
mal. The patient reached appropriate developmental 
milestones. Russell-Silver syndrome was suspected, but 
molecular testing was negative. We identified a homozy-
gous mutation in  OBSL1  (c.2134+1C>T) at a conserved 
splice site.  OBSL1  is one of the three genes (along with 
 CUL7  and  CCDC8 ) known to cause the 3-M syndrome 
 [20] . Notably, there is considerable overlap in clinical fea-
tures between the 3-M syndrome and Russell-Silver syn-
drome  [21] . Although hypergonadotropic hypogonad-
ism has been previously associated with 3-M syndrome 
 [11] , the patient did not have this feature upon subse-
quent clinical evaluation (though the subject is currently 
only 14 years old).
 Patient P07 is a Caucasian female born SGA (2.25 kg) 
as twin A of a term uncomplicated pregnancy. The pa-
tient experienced developmental delay most notable for 
significant language delay. In addition to short stature, 
she has a history of hypothyroidism. The patient also has 
asymptomatic bilateral renal cysts, tethered cord, and se-
vere scoliosis. Bone age was delayed as evaluated by the 
Greulich-Pyle method. Physical examination revealed a 
mildly dysmorphic facial appearance with V-shaped na-
res, short philtrum, slightly beaked nose, and moderate 
 Table 3.  Pathogenic variants identified
Subject
No.
Gene Inheritance
pattern
Position Frequency Functional 
annotation
AA change Function Associated 
diseases
P02 B4GALT7 compound
heterozygous
Chr 5: 177035995
Chr 5: 177031251
NA
0.000077
missense
missense
L41P R270C proteoglycan synthesis progeroid variant 
of Ehlers-Danlos 
syndrome
P07 SRCAP de novo
heterozygous
Chr 16: 30748691 NA nonsense R2444* chromatin remodeling and 
transcription coactivator
Floating Harbor 
syndrome
P09 OBSL1 autosomal
recessive
Chr 2: 220431551 NA splice site
donor
NA cell scaffolding protein 3-M syndrome
P11 CUL7 autosomal
recessive
Chr 6: 43013346 NA frame shift c.2837_2840dupAGAT cell scaffolding protein 3-M syndrome
P14 FAM111A de novo
heterozygous
Chr 11: 58920847 NA missense R569H unknown Kenny-Caffey 
syndrome
 The table lists the causal variants we have identified for the 5 patients for 
which we identified a genetic cause of the short stature. Variant location, 
reference and variant alleles are reported from hg19 coordinates. Minor allele 
frequency is based on the overall allele frequency in the NHLBI Exome Vari-
ant Server (ESP 6500 release) (NHLBI GO exome variant server). Function-
al effect was assessed with PolyPhen2 prediction tool, which estimates the 
effect of missense variants (Adzhubei, 2010). A score of 0.00 is least likely to 
perturb protein function, while a score of 1.00 indicates a missense variant 
that is mostly likely to perturb protein function. Functional annotation of 
SNPs was assessed using SnpEff 2.0.5 (Cingolani, 2012 [18]) and validated 
manually. Protein function was summarized using information found in the 
UniProt database. The OMIM database was used to identify any known dis-
ease associations. Additional variants that passed our filtering criteria for 
these patients are listed in online supplementary table 2.
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scoliosis. We identified a de novo heterozygous point 
mutation (c.7330C>T) causing a p.Arg2444 * nonsense 
mutation in the last exon of the  SRCAP  gene. Mutations 
in  SRCAP  are known to cause the Floating-Harbor syn-
drome  [22] , and the patient’s mutation is the most fre-
quent mutation identified in a cohort of 52 patients with 
Floating-Harbor syndrome  [10] .
 Patient P14 is a female who was born of a normal preg-
nancy and reached appropriate developmental mile-
stones. The patient experienced failure to thrive in infan-
cy requiring hospitalization. Testing at the time revealed 
elevated liver enzymes which self-resolved. Review of sys-
tems is notable for severe myopia but no other ophthal-
mological abnormalities, impaired dentition, and delayed 
primary eruption of teeth. Facial appearance demon-
strates a prominent forehead, a flat nasal bridge, and a 
curved and upturned nose. Skeletal survey was notable 
for bilateral coxa valga and mild medullary stenosis and 
cortical thickening of the long bones, particularly the fe-
mur. Growth hormone levels were normal. The patient 
was variably treated with GH and IGF-1 therapy with an 
overall moderate response (online suppl. File 1).  The pa-
tient also demonstrated early normal pubertal onset and 
was treated with leuprolide. Importantly, calcium, phos-
phate, and parathyroid hormone levels were all normal. 
We identified a de novo heterozygous point mutation 
(c.1706G>A) in  FAM111A causing a missense change 
(p.Arg569His). This is a known recurrent de novo variant 
causing the Kenny-Caffey syndrome, although she is the 
first patient with this diagnosis with documented normo-
calcemia  [23, 24] .
 Additional Consideration of Dominant Inheritance 
 For families P04 and P05, we additionally considered 
dominant modes of inheritance, as for these two families, 
it was less clear if other family members were affected. For 
family P04, both the father (–2.65 SD) and sister (–2.32 
SD) had milder short stature, while in family P05, the fa-
ther had significant short stature (–3.46 SD) and the 
brother had mild short stature (–2.42 SD). Therefore, we 
considered dominant modes of inheritance with trans-
mission from the father to the patient and sibling, or to 
the patient alone. When considering the patients’ siblings 
as affected, we identified 30 rare heterozygous non-syn-
onymous variants in family P04 and 29 such variants in 
family P05 (online suppl. tables 3, 4). When considering 
the patients’ siblings as unaffected, we identified 17 rare 
non-synonymous variants in family P04 and 28 such 
 variants in family P05 (online suppl. tables 3, 4). We did 
not identify any variants that were clearly causal, but we 
do note one interesting missense variant in  NPR2
 (p.E389D) in family P04 that was seen in the patient, her 
father, and her sister. Although heterozygous variants in 
 NPR2  are associated with short stature  [25, 26] , Poly-
Phen2 predicted the variant to be benign and this is not a 
previously reported pathogenic variant. We therefore did 
not have enough evidence to assign causality for this vari-
ant. In family P05, there was a frameshift mutation 
NM_033360.2:c.556_557insT in the last exon of an alter-
native transcript of  KRAS  that was present in the 3 af-
fected members of the family .  Activating heterozygous 
mutations in  KRAS  are known to cause various RASopa-
thies associated with short stature. However, as this mu-
tation is a frameshift (making it more likely to cause de-
creased function) and it occurs in an alternative tran-
script, it is unlikely that this mutation is the cause of the 
short stature. Furthermore, the affected individuals do 
not have any of the clinical features consistent with a 
 RASopathy; thus, we do not believe that the frameshift 
mutation in  KRAS is the cause of the patient’s short stat-
ure.
 Discussion 
 Short stature is a common reason for visits to pediatric 
clinics, but for most patients, a cause of the short stature 
cannot be identified. This inability to identify a cause for 
these patients hampers clinicians’ ability to effectively 
manage and treat many of these patients. However, given 
the strong role that genetics plays in regulating human 
height, it is likely that many patients will have a genetic 
cause of their short stature. Whole exome sequencing pro-
vides the opportunity to rapidly assess for coding variants 
throughout the genome and can be highly advantageous 
for the diagnosis of rare monogenic syndromes that are 
difficult to clinically diagnose otherwise. In our cohort, we 
were able to provide a genetic diagnosis in 5 out of 14 pa-
tients. We also generated and report candidate variants in 
the remaining 9 patients, which will allow other research-
ers studying short stature or other genetic syndromes to 
cross-reference with our list for potential overlap.
 Our study demonstrates how whole exome sequenc-
ing can be effectively used to identify genetic causes of 
disease. By obtaining samples from unaffected members 
of the same family, we can effectively identify de novo 
and inherited variants. Considering only rare variants 
(minor allele frequency <1% in reference databases), we 
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are able to generate a tractable list of candidate variants/
genes for each patient that is amenable to interpretation. 
Through this approach, we were able to identify the caus-
al gene in 36% of families analyzed. Our sample size is 
quite small, limiting our ability to generalize our find-
ings. However, our diagnostic yield is comparable to that 
found in a larger study of clinical exome sequencing ap-
plied to a wide range of phenotypes  [27] . As an addition-
al caveat, we intentionally selected patients with signifi-
cant short stature thus representing the more severe end 
of the spectrum of patients seen by pediatric endocri-
nologists, which likely increased our yield. Nonetheless, 
applied in the pediatric endocrinology clinic setting, our 
results indicate that a significant proportion of patients 
with severe short stature could receive a genetic diagno-
sis. Larger studies of more varied patient populations are 
needed to better understand the efficacy of diagnostic 
whole exome sequencing for patients with short stature. 
As sequencing and interpretation technologies improve, 
the diagnostic yield is likely to increase. We note that se-
quencing of the unaffected sibling is not always neces-
sary, but can aid in filtering out variants also present in 
the unaffected sibling.
 In current clinical practice, a traditional candidate 
gene approach is taken where clinicians order specific 
tests based on clinical features resembling a known syn-
drome. This approach can impede diagnosis of atypical 
cases, in which the relevant syndrome is unlikely to be 
considered by the clinician. In contrast, whole exome se-
quencing considers the vast majority of the coding re-
gions of the genome without a preexisting clinical suspi-
cion, thus allowing for the diagnosis of atypical presenta-
tions of rare syndromes. This is typified by patient P02, 
whom we diagnosed with the progeroid form of Ehlers-
Danlos syndrome. Although the syndrome resulting 
from  B4GALT7  deficiency had been previously charac-
terized by a progeroid facial appearance, our patient did 
not have progeroid features despite having causal muta-
tions in  B4GALT7  [19] , and his description has helped 
refine the phenotypic spectrum of this disorder. Patients 
with Kenny-Caffey syndrome (including patients with 
the same causal variant as our patient P14) have been de-
scribed as having hypoparathyroidism and concomitant 
hypocalcemia  [23, 24] . By contrast, patient P14 demon-
strated normal blood calcium, phosphate, and parathy-
roid hormone levels both in infancy and as an adolescent. 
As we learn more about the variation in clinical presenta-
tion of various gene disorders, ‘atypical’ presentations 
may actually become more prevalent than the ‘classic’ 
textbook syndromic presentations.
 It is interesting to note that we identified the 3-M syn-
drome in 2 patients (P09 and P11) in our cohort. The 3-M 
syndrome is believed to be extremely rare, with roughly 
200 patients reported worldwide, but is likely significant-
ly underdiagnosed  [28] . Our observation of 2 patients in 
our small cohort is consistent with substantial underdiag-
nosis in pediatric clinics. The syndrome bears strong phe-
notypic resemblance to the Russell-Silver syndrome  [21] 
and 1 of our patients (P09) was evaluated for Russell-Sil-
ver syndrome. Thus, we believe that pediatricians and pe-
diatric endocrinologists should be more aware of the 3-M 
syndrome, and consider this diagnosis in all patients with 
negative testing for Russell-Silver syndrome. The diagno-
sis of 3-M syndrome can have important clinical ramifi-
cations as some patients with this syndrome develop hy-
pergonadotropic hypogonadism  [11] .
 Our entire approach to exome analysis is predicated on 
the assumption that these patients’ short stature is due to 
monogenic highly penetrant rare genetic variants follow-
ing a classic pattern of mendelian inheritance. This sce-
nario is clearly an oversimplification, but it is currently the 
most tractable interpretive approach for exome data anal-
ysis and is also the approach that is taken in clinical exome 
interpretation. This standard approach has several limita-
tions. First, this approach largely ignores the possibility of 
genetic variants in multiple genes contributing to the 
short stature (i.e. oligo- or polygenicity). Second, we did 
not analyze variants that are not rare (>1% minor allele 
frequency in reference databases), although these variants 
are unlikely to have a large effect on stature. Additionally, 
we also only analyzed non-synonymous variants, although 
it is well known that synonymous changes can perturb 
gene expression and function. We did not consider non-
coding variants, epigenetic changes, and somatic changes 
(i.e. non-germline), as these are not captured by whole 
exome sequencing and are not currently amenable to in-
terpretation. Finally, we note that it can be difficult to de-
finitively assign other family members as affected or unaf-
fected (see discussion above for patients P04 and P05). 
This caveat is important as our strategy is predicated on 
the accurate assignment of phenotypic status and the as-
sumption that causal variants are highly penetrant and 
manifest as consistent phenotypes. Despite these limita-
tions, we were able to identify probable major genetic con-
tributors to short stature in 5 of 14 patients.
 While we were successful in identifying patients with 
rare syndromes for which the underlying genetic cause is 
already known, we were not successful in identifying nov-
el genetic etiologies of short stature in this cohort. There 
are a number of factors that limit our ability to defini-
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tively identify novel pathogenic variants. We can identify 
numerous variants that segregate with the short stature in 
the family, are damaging in silico, and meet our strict al-
lele frequency criteria; however, many of these variants 
are in genes with little or no known biological evidence to 
support or preclude a causal role in short stature. Our ap-
proach also suffers from not having multiplex families or 
other individuals outside of the family with the same syn-
drome, preventing us from cross-referencing variants or 
performing linkage analysis. However, this scenario is not 
atypical in clinical medicine, where the clinician is usu-
ally evaluating an isolated patient with short stature. This 
highlights how large-scale international collaborations 
are needed in which detailed phenotypic and genotypic 
data are freely shared to facilitate the discovery of novel 
genetic causes of short stature.
 We did identify several variants that are compelling 
candidates, but for which we do not have enough evi-
dence at this time to make a convincing case for causality. 
Here we highlight two examples. Patient P01 has a mis-
sense de novo hemizygous change in  BTK,  which is 
known to cause a syndrome of X-linked agammaglobu-
linemia with isolated growth hormone deficiency. Al-
though the patient has growth hormone deficiency, he 
does not have low immunoglobulin levels and it is not 
known if  BTK  mutations can cause GH deficiency in iso-
lation. Patient P08 has compound heterozygous variants 
in  COL2A1,  which is known to cause a variety of skeletal 
dysplasia and short stature syndromes. However, patient 
P08 does not have any known skeletal anomalies, and it 
is unknown if this patient’s variants in  COL2A1  could 
 cause ISS. We have provided lists of all variants that meet 
our filtering criteria with the hope that other researchers 
will encounter other patients with similar clinical features 
and pathogenic variants in the same gene and help to 
nominate causal genes across a cohort of patients.
 In summary, our study outlines and demonstrates an 
approach to whole exome sequencing that can help iden-
tify genetic causes of short stature in patients with severe 
short stature without a known cause. Our approach is ef-
fective in the context of defined genetic syndromes, but in 
isolated families may be less effective in identifying novel 
genetic causes of short stature. Applied in the clinic, whole 
exome sequencing has the potential to reduce the diagnos-
tic odyssey of patients with severe short stature especially 
in those with other clinical and/or biochemical abnormal-
ities suggestive of a genetic syndrome. This process can be 
particularly challenging for patients with relatively non-
specific features who might present to a pediatric special-
ty clinic for evaluation of short stature. However, as new 
genetic causes of short stature and growth disorders are 
being identified, we expect that whole exome sequencing 
will become more widely used in pediatric endocrinology 
clinics and will facilitate obtaining a genetic diagnosis in a 
subset of children with ISS.
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